Biosimilars

Brain Cancer

Neoadjuvant HER2+

Breast Cancer

Business Management

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastrointestinal Cancer

Urothelial Cancer

Prostate Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Non-Hodgkin Lymphoma

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Hematologic Oncology

Immunotherapy in GU Cancers

Immunotherapy in Lung Cancer

Immunotherapy in Melanoma

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Nursing News

Pediatric Oncology

Special Reports in Personalized Cancer Care

Precision Medicine in Oncology®

Sarcomas/TGCT

Supportive Care

Early lung-specific response to atezolizumab plus bevacizumab was associated with longer overall survival in patients with hepatocellular carcinoma with pulmonary metastases.

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis 

Second-line treatment with regorafenib displayed safety in patients with advanced hepatocellular carcinoma who were not eligible for treatment on the phase 3 RESORCE trial, according to data from the phase 2 REGAIN trial.

Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment

The addition of toripalimab to standard-of-care sorafenib in the frontline setting demonstrated preliminary efficacy and tolerability in patients with unresectable hepatocellular carcinoma.

First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma 

Uwe Platzbecker, MD, discusses how the FDA approval of luspatercept for the treatment of anemia in patients who have not had prior treatment with erythropoiesis-stimulating agent and may require regular red blood cell transfusions could change the sequencing of agents for this patient population.

Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS 

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements And Featured Publications

All Publications

CME/CE

Resources

Biomarker Consortium

Interactive Tools

Learning Modules

Presentations

Subscribe

Print Subscription

eNewsletter

Articles

A new agent that subverts myeloma cells from within while also subjecting them to an immune system attack produced impressive responses in combination with dexamethasone in patients with multiple myeloma that had relapsed and stopped responding to all currently available therapies

Potent Oral Agent Acting as Immunotherapy and Targeted Treatment Produces High Response Rate in Certain Patients

Circulating tumor DNA status at the time of postoperative minimal residual disease is a prognostic factor of recurrence for patients with radically resected stage II to IV colorectal cancer 

Efforts Are Underway to Refine Prognostic Value of ctDNA to Guide Adjuvant Therapy in CRC

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: 

The European Commission has granted marketing authorization for Rylaze for use as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients 1 month and older who developed hypersensitivity or silent inactivation to E. coli–derived asparaginase.

European Commission Approves Rylaze for ALL and Lymphoblastic Lymphoma

The first-line combination of pembrolizumab, lenvatinib, pemetrexed, and platinum-containing chemotherapy did not meet the dual primary end points of overall survival and progression-free survival compared with pembrolizumab plus pemetrexed and platinum-containing chemotherapy in patients with metastatic, nonsquamous non–small cell lung cancer in whom EGFR-, ALK- or ROS1-directed therapies were not indicated.

Pembrolizumab/Lenvatinib Regimens Miss Survival End Points in Metastatic NSCLC

The Webinars section comprises webinars with oncology experts sharing insights on clinical advances in oncology. Watch more on OncLive.

Webinars | Clinical Oncology Webinars & Registration | OncLive

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

Twitter

LinkedIn

Youtube

Spotlight

REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Share your views with OncChats 

Specialty

Register for our live webinar to gain insights and expert perspectives on 

. Our distinguished faculty will discuss best practices and resources for health care providers. HCP attendees will be able to submit questions directly to our faculty during this interactive presentation.

Define what HRD is, and how it relates to ovarian cancer development and disease progression

Discuss similarities and differences between somatic and germline HRD testing, sampling considerations, and available methodologies

Share best practices and clinical insight into how and when providers should order HRD testing for their patients with ovarian cancer

Optimizing Homologous Recombination Deficiency (HRD) Testing Paradigms in Ovarian Cancer

Register for our live webinar to gain insights and perspectives on a treatment option in advanced non-small cell lung cancer. HCP attendees will be able to submit questions to our faculty during the event.


Examine personalized medicine in advanced NSCLC

Understand the history of an immunotherapy option in multiple indications

Present the clinical evidence and Important Safety Information for an immunotherapy option in certain adult patients with advanced NSCLC

Review how to initiate treatment with this immunotherapy in appropriate patients

Personalizing Care: Treatment Considerations for Certain Patients with Advanced NSCLC

Health care providers, join us on February 13 as a panel of expert oncologists consider the role of HER2 expression in 

and review novel targeted therapies in this setting. 

today for our virtual broadcast to secure your seat.

Review important biologic pathways in colorectal cancers and best practices in biomarker testing

Discuss HER2 aberrations in colorectal cancers

Share insight on the role of HER2-targeted therapies and analyze the treatment options for colorectal cancers

HER2-Positive Colorectal Cancer: Novel Approaches

Register for our virtual broadcast to gain insights and expert perspectives on the multidisciplinary approach to 

. Our distinguished faculty will discuss best practices and resources for biomarker testing. 



Take an in-depth look at how medical oncologists and pathologists collaborate regarding biomarker identification

Obtain insight on best practices for identifying patients that may now be eligible for treatment with newly approved targeted therapies

Identify tools, resources, and/or interventions that would assist in the successful implementation of a consistent, multidisciplinary approach to biomarker testing

Precision Medicine: A Collaborative and Multidisciplinary Approach to Identifying Biomarkers

Register today to join us for an exclusive event on December 8, 2022. You and your colleagues have the 

option of joining us live, in-person at 9 locations across the US 

or virtaully from the comfort of your home or office. Discover new insights on 

 (HCC) designed to improved patient outcomes. 

Discuss current frontline treatment options and unmet needs for patients with advanced HCC

Share expert insight on recent updates to the HCC treatment armamentarium

Analyze new data and therapies on the horizon for unresectable HCC

7:00pm ET | 6:00pm CT | 5:00pm MT | 4:00pm PT

9:00pm ET | 8:00pm CT | 7:00pm MT | 6:00pm PT

Gaining Ground: New Options for Advanced HCC

Register for our Live Peer Exchange® to gain new insights and expert perspectives on improving clinical outcomes in

 Our virtual event allows HCP participants to submit questions directly to our faculty. 




Review key data updates in relapsed/refractory MM

Discuss how the recent data can be applied to clinical practice in the treatment of patients with MM

Obtain insights on how available and emerging therapies can be optimally sequenced to improve patient outcomes in MM

The Evolving Treatment Landscape in Multiple Myeloma: An Expert Case-Based Discussion

Register for our live webinar to gain new insights and perspectives on improving clinical outcomes in 

. HCP attendees will be able to submit questions to our faculty during the event.

 

Efficacy and safety findings from a study of an FDA-approved treatment for previously treated metastatic SCLC

Considerations for dosing, administration, and patient counseling

Exploring a treatment option for patients with previously treated Metastatic Small Cell Lung Cancer

Register for our live webinar to gain insights and perspectives on treatment consideration for 

. HCP attendees will be able to submit questions to our faculty during the event.


Identifying patients at high risk for developing locally advanced BCC

Methods for evaluating treatment options from a multidisciplinary perspective

A review of considerations for systemic therapy in patients with locally advanced BCC

A review of the clinical data of a systemic therapy option

Co-managing Patients with Locally Advanced Basal Cell Carcinoma (BCC) in an Evolving Treatment Landscape

OncLive® invites you to register for our live multiple myeloma 

 where our distinguished faculty will share their authoritative insights, opinions, and perspectives on important issues facing today's HCPs.

is complimentary for health care providers.

Review the available evidence around disparities in multiple myeloma care among racial and minority populations

Evaluate the factors contributing to disparities in multiple myeloma

Discuss strategies to address disparities in multiple myeloma care among racial and minority populations

Addressing Disparities in Multiple Myeloma Care Among Racial and Ethnic Minority Populations

Register today to join our live webinar on July 19. During our virtual event, HCP attendees will have the opportunity to submit questions to our faculty. Secure you virtual seat today.

Small Cell Lung Cancer: A review of epidemiology, treatment landscape, and long-term management

Register for our live webinar to gain new insights and perspectives on breast cancer. Our virtual event allows HCP participants to submit questions directly to our faculty.



Testing practices in patients with early stage breast cancer

Selection of adjuvant treatment in patients with early stage HER2-negative and triple negative breast cancers

Strategies for sequencing in patients with HER2-positive metastatic breast cancer

Data updates in the treatment of patients with breast cancer from recent conferences


New Frontiers in Breast Cancer: Updates and Advances in Treatment

Register today to join our live webinar on June 16th. During our virtual event, HCP attendees will have the opportunity to submit questions to our faculty. Secure you virtual seat today.

Discuss practice patterns and data supporting use of front-line immune checkpoint inhibitors in patients with advanced NSCLC

Identify appropriate patient populations for use of dual immune checkpoint inhibitor regimens

Examine treatment options for patients with low or no PDL-1 expression

The Current and Future State of Immune Checkpoint Inhibitors in NSCLC

 (NSCLC) treatment landscape. Our virtual event allows HCP participants to submit questions directly to our faculty.



Take an in-depth look at antibody drug conjugate (ADC) technology and those that are in the pipeline for NSCLC

Gain insight on how ADCs have the potential to impact the treatment landscape of NSCLC

Review strategies for managing adverse events associated with ADCs in NSCLC

On the Horizon in NSCLC: Antibody Drug Conjugates

For three days, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented during the annual oncology conference.

Register today and tune in for our exclusive broadcasts each evening at 7:00PM ET.

OncLive® News Network: On Location at ASCO 2022

Register today to join our live webinar on April 12th. During our virtual event, HCP attendees will have the opportunity to submit questions to our faculty. 

Efficacy and safety findings from a study of an FDA-approved treatment for previously treated metastatic SCLC Considerations for dosing, administration, and patient counseling

Join the Baylor College of Medicine for the 

Webinars

Latest Conference Coverage